FITC Anti-Mouse CD25 (PC61.5)

Liang D, Zuo A, Shao H, Born WK, O´ Brian R, Kaplan HJ, and Sun D. 2012. J. Immunol. 188: 5785-5791. (in vivo blocking)

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, and Waldmann TA. 2012. Proc. Natl. Acad. Sci. 109:6187-6192. (in vivo Treg depletion)

Billiard F, Lobry C, Darrasse-Jeze G, Waite J, Liu et al. 2012. Blood. 119: 4656-4664. (in vivo Treg depletion)

Tang S, Moore ML, Grayson JM and Dubey P. 2012. Cancer Res. 72: 1975-1985. (in vivo Treg depletion)

Lee L-F, Logronio K, Tu GH, Zhai W, Ni I, Mei L, Dilley J, Yu J, et al. 2012. Proc. Natl. Acad. Sci. 10.1073. (Flow cytometry).

10F.9G2, J43, PC61 Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)

Leithauser F, Meinhardt-Krajina T, Fink K, Wotschke B, Moller P and Reimann J. 2006. Am. J. Pathol. 168(6): 1898-1909. (Immunohistochemistry - frozen tissue)

Hashimoto N, Nabholz M, MacDonald HR, and Zubler RH. 1986. Eur. J. Immunol. 16(3): 317-320. (Blocking)

Ceredig R, Lowenthal JW, Nabholz M, and MacDonald R. 1985. Nature. 314:98-100 (Immunohistochemistry)

Lowenthal JW, Zulber RH, Nabholz M, and MacDonald HR. 1985. Nature. 315(6021): 669-672. (Immunoprecipitation, Blocking)